Torna alla panoramica
SNCTP000005401 | EUCTR2016-001784-36 | BASEC2022-02264

MAKEI V: Eine internationale klinische Studie für Kinder, Jugendliche und junge Erwachsene mit bösartigen, extrakraniellen Keimzelltumoren.

Base di dati: BASEC (Importata da 08.11.2024), WHO (Importata da 07.11.2024)
Cambiato: 5 set 2024, 07:56
Categoria di malattie: Altro cancro

Descrizione riassuntiva della sperimentazione (Fonte di dati: BASEC)

Bösartige Keimzelltumore treten meist in den Keimdrüsen, also Eierstöcken oder Hoden, auf, aber auch an anderen Orten des Körpers. Sie kommen in jeder Altersgruppe vor, vom Säuglings- bis ins junge Erwachsenenalter. Durch Operation und Chemotherapie konnten die Heilungschancen in den letzten Jahrzehnten drastisch verbessert werden. Diese Massnahmen sind jedoch nicht selten mit schweren Nebenwirkungen verbunden. Bei der Therapie von Keimzelltumoren kann die Therapie langfristige Folgen wie Schwerhörigkeit und Nierenschädigung nach sich ziehen. Angesichts der sehr guten Gesamtprognose bei bösartigen Keimzelltumoren ist die Qualität des Überlebens heute ein wichtiger Aspekt bei der Gestaltung der Behandlung geworden. Dementsprechend liegt zunehmend der Schwerpunkt auf der Verringerung der Behandlungslast bei gleichzeitiger Aufrechterhaltung der Wirksamkeit der Behandlung. MAKEI V ist eine internationale Therapieoptimierungsstudie, welche bösartige, ausserhalb des Zentralnervensystems gelegene, Keimzelltumore bei Kindern und Jugendlichen sowie bei jungen erwachsenen Patientinnen untersucht. Ein Hauptziel der Studie liegt darin, die Wirksamkeit und Nebenwirkungen der zwei Substanzen Cisplatin und Carboplatin kontrolliert zu vergleichen.

Malattie studiate(Fonte di dati: BASEC)

Bösartige, extrakranielle Keimzelltumore

Health conditions (Fonte di dati: WHO)

Extracranial germ cell tumours of any malignant histology, primary site and stage;Therapeutic area: Diseases [C] - Cancer [C04]

Malattia rara (Fonte di dati: BASEC)

No

Interventi esaminati (p. es. medicamento, terapia, campagna) (Fonte di dati: BASEC)

Je nach Lokalisation und Ausbreitung der Erkrankung werden die Patientinnen und Patienten in verschiedene Risikogruppen eingeteilt. Die Bekämpfung der Keimzelltumoren erfolgt je nach Risikogruppe durch eine alleinige Operation oder durch eine Kombination von Operation und Chemotherapie:
• Niedriges Risiko: Operation
• Mittleres Risiko: Operation und 2 Kurse Chemotherapie
• Hohes Risiko: Operation und 4 Kurse Chemotherapie
• Höchstes Risiko: Operation und 4 Kurse Chemotherapie, davon 3 dosis-intensivierte Chemotherapie.
Falls die Patientinnen und Patienten mittels Chemotherapie behandelt werden, werden sie nach dem Zufallsprinzip in verschiedene Therapiegruppen eingeteilt (Randomisierung). Die zwei Therapiegruppen unterscheiden sich lediglich darin, ob die Substanz Carboplatin oder Cisplatin verabreicht wird. Beide Medikamente werden seit vielen Jahren erfolgreich zur Behandlung von Keimzelltumoren eingesetzt. Von Carboplatin weiss man, dass dies zu weniger Nebenwirkungen führt. Durch den kontrollierten Vergleich vom bisherigen Cisplatin mit Carboplatin im Rahmen der Studie kann untersucht werden, ob durch den Einsatz von Carboplatin gleich gute Überlebensraten mit geringeren therapiebedingten Nebenwirkungen erreicht werden.

Interventions (Fonte di dati: WHO)


Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: CISPLATIN
CAS Number: 15663-27-1
Concentration unit: mg/m2 milligram(s)/square meter
Concentration type: up to

Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: CARBOPLATIN
CAS Number: 41575-94-4
Concentration unit: mg/m2 milligram(s)/square meter
Concentration type: up to

Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: ETOPOSIDE
CAS Number: 33419-42-0
Concentration unit: mg/m2 milligram(s)/square meter
Concentration type: up to

Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: IFOSFAMIDE
CAS Number: 3778-73-2
Concentration unit: mg/m2 milligram(s)/square meter
Concentration type: up to

Criteri per la partecipazione alla sperimentazione (Fonte di dati: BASEC)

• Alter bei Diagnose unter 18 Jahren (oder bei Patientinnen mit Eierstocktumoren unter 30 Jahren)
• Bestätigte Diagnose eines bösartigen, extrakraniellen Keimzelltumors
• Schriftliche Einwilligungsbestätigung zur Studienteilnahme

Criteri di esclusione (Fonte di dati: BASEC)

• Schwangerschaft oder Stillen
• HIV Positivität
• Impfung mit einem Lebendimpfstoff innerhalb zwei Wochen vor Beginn der Studienbehandlung

Inclusion/Exclusion Criteria (Fonte di dati: WHO)

Inclusion criteria:
- Confirmed extracranial MGCT up to 17 11/12 years of age or patients with ovarian primaries up to 29 11/12 years of age on the date of written informed consent
- Written informed consent prior to trial entry of parents and/or patient
- Diagnosis of a chemotherapy-naïve extracranial MGCT
- Karnofsky-Index of >70% or ECOG-Status 0-II
- Negative pregnancy test within 7 days prior to start of treatment for female patients of childbearing potential, in case of ß-HCG secreting MGCT pregnancy has to be excluded by appropriate methods

Note: Any patient who is of reproductive age should agree to use adequate contraception for the duration of the trial treatment and until at least 12 months after end of therapy.
Are the trial subjects under 18? yes
Number of subjects for this age range: 300
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 60
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
Exclusion criteria in general:
- Pregnancy
- Lactation
- Incomplete data at trial entry preventing risk group allocation
- HIV-positivity
- Live vaccine immunization within two weeks before start of protocol treatment
- Sexually active adolescents not willing to use highly effective contraceptive method (pearl index <1) until 12 months after end of chemotherapy

- Current or recent (within 30 days prior to date of informed written consent) treatment with another investigational drug or participation in another interventional clinical trial, except trials with different end points than MAKEI V that can run in parallel to MAKEI V without influencing that trial, e.g., trials on antiemetics, antimycotics, antibiotics, strategies for psychosocial support, etc.
- Any other medical, psychiatric or drug related condition, or social condition incompatible with protocol treatment.

Exclusion criteria in special indication:
- Second malignancies
- Negative preoperative tumour markers AFP and ß-HCG and solely pure teratoma histology
- Known hypersensitivity against Cisplatin, Carboplatin, Etoposide, Ifosfamide or other ingredients of the medicinal product
- Hearing impairment Grade 3 and 4 (CTCAE Vers.4.03)

Altri dati sulla sperimentazione nel registro primario dell’OMS

https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001784-36

Altri dati sulla sperimentazione dalla banca dati dell’OMS (ICTRP)

https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2016-001784-36
Altre informazioni sulla sperimentazione

Data di registrazione della sperimentazione

8 apr 2019

Inserimento del primo partecipante

12 ago 2019

Stato di reclutamento

Authorised-recruitment may be ongoing or finished

Titolo scientifico (Fonte di dati: WHO)

Multicentre prospective trial for extracranial malignant germ cell tumours including a randomized comparison of Carboplatin and Cisplatin - MAKEI V

Tipo di sperimentazione (Fonte di dati: WHO)

Interventional clinical trial of medicinal product

Disegno della sperimentazione (Fonte di dati: WHO)

Controlled: yesRandomised: yesOpen: yesSingle blind: noDouble blind: noParallel group: yesCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: yesPlacebo: noOther: noNumber of treatment arms in the trial: 2

Fase (Fonte di dati: WHO)

Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no

Punti finali primari (Fonte di dati: WHO)

Main Objective: To assess in a randomized comparison whether the efficacy of Carboplatin is not inferior to Cisplatin in malignant germ cell tumours (MGCT) of intermediate, high and very high risk with regard to Event-free-survival (EFSr);Secondary Objective: 1. Evaluation of EFS/OS rates in the defined risk-groups compared to results of MAKEI 96 and published data
2. Evaluation of toxicity in randomized patients in respect to numbers of days in hospital, numbers of applied platelet and red blood cell transfusions
3. Evaluation of ototoxicity, nephrotoxicity, cardiotoxicity and fertility relevant endocrine outcomes under and after treatment chemotherapy
4. Evaluation of patient-reported-outcomes
5. Implementation of standardized documentation of surgical procedures and evaluation of potential impact of variations in procedures on EFS
6. Evaluation of risk stratification for therapy implemented in MAKEI V based on standardized staging and pathological evaluation in comparison to MAKEI 96
7. Evaluation of radiological response after two or four cycles of chemotherapy
8. Evaluation of standard tumour marker kinetics after every cycle of chemotherapy
;Primary end point(s): Event-free survival, defined as minimum time from the date of randomization to the following events (EFSr):
- Death from any cause
- Progressive disease, defined as increase of standard tumour marker with or without expansion of tumour mass/metastases
- Viable tumour cells at time of final surgery
- Relapse
- Second malignancy
- or the date of the last follow-up
This relates to patients randomized to Carboplatin or Cisplatin.;Timepoint(s) of evaluation of this end point: Any timepoint from the date of randomization to one of the defined events.

Punti finali secondari (Fonte di dati: WHO)

Timepoint(s) of evaluation of this end point: Any timepoint from the date of randomization to one of the defined events or analysis.;Secondary end point(s): - Event-free survival (EFS), defined as minimum time from the date of diagnosis to any of the events described above or to last follow-up, of all patients included in MAKEI V in respect to the defined MAKEI V risk groups
- Overall survival (OS), defined as minimum time from the date of diagnosis to death of any cause or to last follow-up, of all patients included in MAKEI V in respect to the defined MAKEI V risk groups
- Health economic parameter, e.g. hospitalization days during treatment, number of blood transfusions, in respect to treatment with Carboplatin or Cisplatin
- Short and late toxicities according to CTCAE v4.03
- Assessment of safety: Adverse events and laboratory abnormalities, CTCAE v4.03 grade, timing, seriousness and relatedness.
- Fertility relevant endocrine outcomes, e.g. Estrogen, AMH, LH, FSH, Inhibin B.
- Patient reported outcomes including HRQoL, fatigue, sexual function and fertility outcomes (in adult patients)
- Determination of risk for relapse in respect to used surgical intervention
- Radiological response rate after two (and if applicable four) cycles of either Carboplatin or Cisplatin chemotherapy
- Standard tumour marker levels after every cycle of either Carboplatin or Cisplatin chemotherapy

Contatto per informazioni (Fonte di dati: WHO)

Deutsche Krebshilfe

Risultati della sperimentazione (Fonte di dati: WHO)

Sintesi dei risultati

Multicentre prospective trial for extracranial malignant germ cell tumours including a randomized comparison of Carboplatin and Cisplatin

Collegamento ai risultati nel registro primario

ancora nessuna informazione disponibile

Informazioni sulla disponibilità dei dati dei singoli partecipanti

ancora nessuna informazione disponibile

Siti di esecuzione della sperimentazione

Siti di esecuzione in Svizzera (Fonte di dati: BASEC)

Aarau, Basilea, Bellinzona, Berna, Ginevra, Losanna, Luzern, San Gallo, Zurigo

Paesi di esecuzione (Fonte di dati: WHO)

È possibile che la Svizzera non appaia ancora come paese di esecuzione perché non è ancora stata registrata nel registro primario dell’OMS.
Germany

Contatto per maggiori informazioni sulla sperimentazione

Dati della persona di contatto in Svizzera (Fonte di dati: BASEC)

KD Dr. med. Sabine Kroiss
+41 44 266 74 55
sabine.kroiss@kispi.uzh.ch

Contatto per informazioni generali (Fonte di dati: WHO)

Dr. Judith Schilling
Venusberg-Campus 1
Studienzentrale Studienzentrum Bonn (SZB)
004922828719037
studienzentrale-szb@ukbonn.de

Contatto per informazioni scientifiche (Fonte di dati: WHO)

Dr. Judith Schilling
Venusberg-Campus 1
Studienzentrale Studienzentrum Bonn (SZB)
004922828719037
studienzentrale-szb@ukbonn.de

Autorizzazione da parte della commissione d’etica (Fonte di dati: BASEC)

Nome della commissione d’etica che rilascia l’autorizzazione (nel caso di studi multicentrici solo la commissione direttiva)

Kantonale Ethikkommission Zürich

Data di autorizzazione da parte della commissione d’etica

07.03.2023

Altri numeri di identificazione delle sperimentazioni

Numero di identificazione della sperimentazione della commissione d’etica (BASEC-ID) (Fonte di dati: BASEC)

2022-02264

Secondary ID (Fonte di dati: WHO)

PAED-201601
Torna alla panoramica